The donation decline means Canadian Blood Services may need to start accessing a stored inventory of blood donations, which could impact patient care. Here’s how to book a donation appointment.

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy and safety data from Haisco's broad completed clinical development program in ...

Objective: To investigate risk factors for postoperative incisional infection after spinal tumor surgery, develop a risk ...

Almost everyone knows that our blood carries oxygen to all parts of the human body, from the toes to the brain. We don’t think about how the red blood cell ...

Hepcidin and ferritin-based indices help identify patients with active inflammatory bowel disease who are less likely to respond to iron therapy.

Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...

The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase ...

Stock drops after development setback Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company ...

Agios Pharmaceuticals said on Tuesday it is discontinuing development of its sickle cell disease treatment ​after trial ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a ...

Agios Pharmaceuticals said on Tuesday it will ​stop development of ‌its sickle cell disease treatment, sending its shares down 14% in premarket ‌trading. The ​trial ⁠was designed to ⁠characterize the ...